Stockscreener 앱 받기
7.12
0.00%
0.00
시간 외 거래:
7.15
0.03
+0.42%
Solid Biosciences Inc 주식(SLDB)의 최신 뉴스
Solid Biosciences (SLDB) Strengthens Financial Position with Inc - GuruFocus
Solid Biosciences Reports Positive Interim Data for SGT-003 and Advances Clinical Programs in Duchenne Muscular Dystrophy, Friedreich’s Ataxia, and CPVT - Quiver Quantitative
Solid targets Phase 3 Duchenne dosing in April after positive data - Stock Titan
Solid Biosciences Inc. spotlights leadership role in Friedreich ataxia research collaboration - Traders Union
Geopolitics Watch: What analysts say about Solid Biosciences Inc stockWeekly Trade Review & Reliable Entry Point Alerts - baoquankhu1.vn
PERCEPTIVE ADVISORS LLC Increases Stake in Solid Biosciences Inc - GuruFocus
RA Capital boosts Solid Biosciences (SLDB) ownership to 9.9% with March buys - Stock Titan
H.C. Wainwright Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences reports interim data from Duchenne gene therapy trial - Investing.com Nigeria
Citizens reiterates Solid Biosciences stock rating on trial data By Investing.com - Investing.com Canada
Boxer Capital Management LLC Takes Position in Solid Biosciences Inc. $SLDB - MarketBeat
Ally Bridge Group NY LLC Has $3.39 Million Stock Position in Solid Biosciences Inc. $SLDB - MarketBeat
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Korro Bio (KRRO) and Pharming Group (PHAR) - The Globe and Mail
Friedreich Ataxia research spotlight as Solid Biosciences advances SGT-212 clinical trials - Traders Union
Options Flow: What analysts say about Solid Biosciences Inc stockExit Point & Technical Buy Zone Confirmations - baoquankhu1.vn
Solid Biosciences reports interim data from Duchenne gene therapy trial By Investing.com - Investing.com Australia
Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start (NASDAQ:SLDB) - Seeking Alpha
Solid Biosciences says interim results reinforce confidence in SGT-003 potential - Yahoo Finance
SLDB: Wedbush Raises Price Target, Maintains Outperform Rating | - GuruFocus
Truist reiterates Buy on Solid Biosciences stock after trial data By Investing.com - Investing.com South Africa
Truist reiterates Buy on Solid Biosciences stock after trial data - Investing.com
Chardan Capital Reaffirms "Buy" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences (SLDB): Chardan Capital Maintains Buy Rating w - GuruFocus
Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data - TipRanks
Barclays Maintains Solid Biosciences (SLDB) Overweight Recommendation - MSN
Solid Bio’s SGT-003 Data Show DMD Gene Therapy Efficacy Without Liver Toxicity - Citeline News & Insights
Solid Biosciences (NASDAQ: SLDB) reports promising SGT-003 Duchenne data - Stock Titan
Perceptive invests $49.9M via warrants in Solid Biosciences (SLDB) - Stock Titan
Perceptive Life Sciences fund acquires 8.9M SLDB pre-funded warrants in Solid Biosciences (SLDB) - Stock Titan
Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned - Benzinga
Solid Biosciences (SLDB) Shares Drop After New Trial Data Releas - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Shares Down 6.3%Time to Sell? - MarketBeat
Solid Biosciences shares fall after gene therapy trial data - Investing.com
Solid Bio falls amid new data for Duchenne drug (SLDB:NASDAQ) - Seeking Alpha
Solid Biosciences shares fall after gene therapy trial data By Investing.com - Investing.com India
Solid Biosciences (SLDB) Reveals Encouraging Interim Data from S - GuruFocus
Solid Biosciences Inc. unveils positive interim data from Duchenne gene therapy trial - Traders Union
Solid Biosciences Reports Positive Interim Data from Phase 1/2 INSPIRE DUCHENNE Trial of SGT-003, Demonstrating Robust Microdystrophin Expression and Encouraging Safety Profile - Quiver Quantitative
Solid Biosciences Provides Interim Positive Clinical Update On Phase 1/2 Inspire Duchenne Trial - TradingView
Gene therapy from Solid Biosciences shows muscle, heart gains in Duchenne children - Stock Titan
Wedbush Reiterates Outperform Rating for SLDB with $14 Price Tar - GuruFocus
Wedbush Reaffirms "Outperform" Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Big Money Moves: Will Solid Biosciences Inc stock recover after earnings2026 Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - Bitget
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
Bain Capital Life Sciences (SLDB) caps Solid Biosciences stake at 9.99% after PIPE - Stock Titan
RA Capital details 9.9% Solid Biosciences (SLDB) ownership position - Stock Titan
Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT - MSN
Solid Biosciences Secures $240 Million in Private Placement - Global Legal Chronicle
SLDB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Solid Biosciences (NASDAQ:SLDB) Reaches New 1-Year HighShould You Buy? - MarketBeat
Solid Biosciences Announces $240 Million Private Placement Financing - The Globe and Mail
Solid Biosciences secures $240M private placement funding By Investing.com - Investing.com Canada
Solid Biosciences Raises $240 Million in Private Placement of Stock and Pre-Funded Warrants - TradingView
Solid Biosciences Inc. announced that it expects to receive $239.972139 million in funding - marketscreener.com
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Bitget
Solid Biosciences (SLDB) Announces $240M Private Placement - GuruFocus
1.20%
0.06%
자본화:
|
볼륨(24시간):